Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Persistent Pulmonary Hypertension of the Newborn
NCT01389856 · Actelion · PHASE3 · terminated · last registry update 2025-02-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “To be compliant with the timelines as agreed with Paediatric Committee (PC) within the Paediatric Investigational Plan” | – | Registry record, Actelion |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EDNRB within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-11-24Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Tadalafil + Ambrisentan (NCT07245680)
- 2025-10-21Results posted on the registry: Janssen Pharmaceutical K.K., Macitentan (NCT05167825)
- 2025-09-16Results posted on the registry: PharmaMar, Lurbinectedin + Bosentan (NCT05072106)
- 2025-09-12Results posted on the registry: Actelion, Macitentan (NCT02932410)
- 2025-07-31Results posted on the registry: Aerogen Pharma Limited, VentaProst (NCT03122730)
- 2025-07-31Results posted on the registry: Aerogen Pharma Limited, VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (NCT04452669)
- 2025-06-27Also stopped (terminated): Actelion, Macitentan + Placebo (NCT04271475)
- 2025-06-22Also stopped (withdrawn): Actelion, Macitentan (NCT01346930)
- 2025-04-22Results posted on the registry: Actelion, Macitentan + Placebo (NCT04271475)
- 2025-03-30Also stopped (withdrawn): Actelion, Macitentan (NCT05731492)
- 2025-02-20Also stopped (withdrawn): Franz Rischard, DO, Opsumit 10 Mg Tablet (NCT03726398)
- 2025-02-04Also stopped (terminated): Actelion, Inhaled Iloprost (5 μg) + Inhaled Placebo (NCT00302211)
- 2025-02-04Also stopped (terminated): Actelion, bosentan (NCT00313196)
- 2025-02-04Also stopped (terminated): Actelion, macitentan 10 mg (NCT03714815)
- 2025-02-04Also stopped (terminated): Actelion, Bosentan (NCT00310830)
- 2025-02-04Also stopped (terminated): Actelion, Macitentan 3 mg + Macitentan 10 mg (NCT01474122)
- 2025-02-03Also stopped (terminated): Actelion, a drug against EDNRB (NCT04955990)
- 2025-02-03Also stopped (terminated): Actelion, Bosentan (NCT00360087)
- 2024-11-12Results posted on the registry: University of Edinburgh, Isosorbide Mononitrate XL (ISMN) + Cilostazol (NCT03451591)
- 2024-11-01Results posted on the registry: United Therapeutics, Treprostinil Inhalation Powder (NCT03950739)
- 2024-10-15Also stopped (terminated): Duke University, Inhaled Iloprost (NCT02170519)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-07-30Results posted on the registry: Liquidia Technologies, Inc., LIQ861 Inhaled Treprostinil (NCT03399604)
- 2024-05-29Phase 3 first posted: Radboud University Medical Center, Endothelin Receptor Antagonist (NCT06432452)
- 2024-03-12Results posted on the registry: University of California, Los Angeles, Macitentan (NCT05373108)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision